Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future
Executive Summary
Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take into Phase III in NASH with the ATLAS combination study data expected in December.